Will SeaStar Medical stock go up?

According to Danelfin AI, SeaStar Medical has today an AI Score of 2/10 (Strong Sell rating), because its probability of beating the market in 3 months (41.48%) is -9.33% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for SeaStar Medical stock?

The SeaStar Medical target price is $15.64 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold SeaStar Medical stock right now?

SeaStar Medical has today a Strong Sell rating (AI Score 2/10), according to Danelfin AI. Its probability of beating the market in 3 months (41.48%) is -9.33% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether SeaStar Medical stock is a good buy .

Is SeaStar Medical undervalued right now?

Based on analysts, the average price target upside for SeaStar Medical is +220.51% (1Y). According to Danelfin AI, SeaStar Medical has today an AI Score of 2/10 (Strong Sell Rating).

What was the price range of SeaStar Medical stock over the past 12 months?

The SeaStar Medical stock price range over the past 12 months has been $2.21 - $12.4.

What is going on with SeaStar Medical stock in the last 3 months?

The SeaStar Medical stock performance in the last quarter has been +31.18%.

Does SeaStar Medical offer dividend payments?

No, SeaStar Medical does not currently pay dividends.

What is the current market capitalization of SeaStar Medical?

SeaStar Medical's market cap is $19.43M, as of 2026-07-02 08:00.

When is the next ICU earnings report date?

ICU will publish its next earnings report on 2026-05-13.

SeaStar Medical Holding Corp (ICU) AI Stock Analysis

Advanced Chart

Custom range

Jul 2, 2025

→

Jul 2, 2026

Custom range

Jul 2, 2025

→

Jul 2, 2026

ICU AI-Powered Stock Analysis

AI Score Explanation

AI Score

Strong Sell

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, SeaStar Medical Holding Corp today receives an AI Score of 2/10, which translates to a Sell rating. The stock has a 41% probability of outperforming the market in the next 3 months, which is 10% lower than the average probability of any stock (51%). The top positive contributor is the EPS Estimate (Next Q) signal, which adds +0.58% to the probability, despite being in the bottom 10% of stocks. The Alpha 1Y signal also contributes positively with +0.50%, ranking in the top 40%. However, the strongest detractors include the Industry (GICS) classification (Health Care Equipment & Supplies) reducing probability by -1.35%, the Chart Pattern (252d) by -1.17%, and the Fear & Greed Index at 31 (extreme fear) by -0.95%. Additional negative impacts come from Maximum Volatility (top 20%) at -0.79%, Operating Profit Margin (bottom 10%) at -0.67%, and Institutional Ownership (bottom 20%) at -0.62%. Notable data points include an extremely negative Operating Profit Margin of -727.88% (bottom 10%), indicating severe operational inefficiency. Institutional Ownership is very low at 3.99% (bottom 20%), suggesting lack of confidence from large investors. Maximum Volatility is in the top 20%, reflecting high price instability. On the positive side, the EPS Estimate (Next Q) is -$0.97 (bottom 10%), but still contributes positively, likely due to expectations of improvement. The Alpha 1Y is -6.07% but ranks in the top 40%, meaning the stock has performed relatively better than peers on a risk-adjusted basis. Overall, the stock faces significant headwinds from poor fundamentals, high volatility, and negative sentiment, resulting in a low AI Score and a Sell rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Growth+0.58%
Expected pace of revenue and earnings expansion
Earnings Quality+0.27%
Stability and reliability of reported earnings

Momentum-4.24%
Direction and strength of recent price movements
Sentiment-2.61%
How analysts and the market view the stock
Valuation-1.23%
How the stock is priced relative to its fundamentals
Volatility-1.10%
How much the stock price tends to fluctuate
Profitability-1.00%
Profitability and operating efficiency metrics

ICU probability advantage of beating the market (3M):

-9.33%

AI Score

Strong Sell

SeaStar Medical (ICU) has an AI Score of 2/10 (Strong Sell) because, according to an overall analysis, it has a probability advantage of -9.33% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of ICU (41.48%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
ICU probability advantage of beating the market (3M)-9.33%
ICU probability of beating the market (3M)41.48%

ICU probability advantage of beating the market (3M): -9.33%

The AI-powered overall analysis of SeaStar Medical (ICU) is based on the 29 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of ICU:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Sentiment	Industry (GICS)	Health Care Equipment & Supplies	N/A	-1.35%
Technical	Chart Pattern (252d)	figure_60	N/A	-1.17%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-0.95%
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	-0.90%
Technical	Maximum Volatility	9.92%		-0.79%
Fundamental	Operating Profit Margin	-727.88%	N/A	-0.67%
Sentiment	Institutional Ownership	3.99%		-0.62%
Sentiment	EPS Estimate (Next Q)	-0.97	N/A	+0.58%
Technical	Distance from KAMA (20d)	0.53%		-0.56%
Technical	Chart Pattern (504d)	figure_6	N/A	-0.51%
Technical	Upgrade to unlock			-0.51%
Technical	Upgrade to unlock			+0.50%
Technical	Upgrade to unlock			-0.47%
Technical	Upgrade to unlock			-0.46%
Technical	Upgrade to unlock			-0.40%

Rest of Alpha Signals: -1.04%

ICU probability advantage of beating the market (3M)Total:-9.33%
ICU AI Score

Significant changes Vs previous day

ICU Short Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$4.88
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro)
Take Profit:$XXXXXPro (XXXXX
Pro
)

ICU Proven Sell Signal & Price Forecast

This is the price chart for ICU from January 1, 2026 until today. The chart indicates, in red, the 109 days when the stock received a Sell/Strong Sell rating (sell signals, AI Score 1 to 3).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Sell signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Sell signals

Forecast:

1 Month
3 Months
6 Months
1 Year

ICU Average Past Performance & Loss Rate

Three months after its 242 Sell signals since July 2026, ICU had an average performance of xxxxxxx and a xxxxxx Loss rate (negative performance).

242 Past ICU Sell Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				-76.87%
Average Alpha				-93.65%
Loss Rate (% Negative Perf.)				91.96%
% Negative Alpha				99.11%

ICU Frequently Asked Questions

Will SeaStar Medical stock go up?
According to Danelfin AI, SeaStar Medical has today an AI Score of 2/10 (Strong Sell rating), because its probability of beating the market in 3 months (41.48%) is -9.33% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for SeaStar Medical stock?
Is it a good time to buy, sell, or hold SeaStar Medical stock right now?
Is SeaStar Medical undervalued right now?
What was the price range of SeaStar Medical stock over the past 12 months?
What is going on with SeaStar Medical stock in the last 3 months?
Does SeaStar Medical offer dividend payments?
What is the current market capitalization of SeaStar Medical?
When is the next ICU earnings report date?

SeaStar Medical Holding Corp Company Profile

SeaStar Medical Holding Corporation is a U.S.-based healthcare technology enterprise, focusing on the innovative development of therapy platforms aimed at mitigating hyperinflammation's deleterious effects on crucial organs. The corporation handles immune responses, strategizing against infections and fostering the repair of damaged bodily tissue.

Additionally, SeaStar Medical is immersed in pioneering product development across multiple therapeutic niches; these include pediatric and adult acute kidney injury within the Continuous Renal Replacement Therapy (CRRT) domain, cardiorenal syndrome tied with congestive heart failure, end-stage renal disease-associated myocardial stunning, and hepatorenal syndrome.

The company's operational hub is situated in Denver, Colorado. With unwavering commitment to its mission and inherent innovation in medical discovery guiding its momentum forward, SeaStar Medical steadily carves its trajectory in this specialized medical segment.

Sector:Health Care
Country:United States
Industry:Health Care Equipment & Supplies
Address:3513 Brighton Blvd, Suite 410, Denver
Employees:17
Website:seastarmedical.com

Pros

Proprietary device technology for inflammation modulation

Addressing critical unmet needs in acute care

Potential for technology platform expansion across indications

High switching costs for integrated hospital protocols

Operating leverage from scalable medical device manufacturing

Cons

Dependency on single product regulatory approval pathway

Substantial capital requirements for clinical development

Uncertainty of reimbursement coverage and pricing negotiation

Competition from existing and emerging inflammation therapies

Reliance on third-party manufacturing and supply chain

Company	AI Score	Compare
WAYWaystar Holding Corp
STESTERIS plc
BSXBoston Scientific Corp
SCNXScienture Holdings Inc

Company	AI Score	Compare
WAYWaystar Holding Corp
STESTERIS plc
BSXBoston Scientific Corp
SCNXScienture Holdings Inc

ICU Stock AI Analysis High Risk